Evaluation of eIF4E Expression in an Osteosarcoma-Specific Tissue Microarray
- 1 October 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Pediatric Hematology/Oncology
- Vol. 33 (7), 524-528
- https://doi.org/10.1097/mph.0b013e318223d0c1
Abstract
The ability to define osteosarcoma (OS) patients at greatest risk for metastatic progression and nonresponsiveness to conventional therapy is currently not possible. Such biomarkers are needed to predict overall prognosis, probability of metastases at diagnosis, and response to chemotherapy. The tissue microarray (TMA) serves as a powerful tool for detecting and validating protein biomarkers across a variety of patients. We constructed a novel outcome-linked TMA to add to and address shortcomings of currently available OS tissue resources. To test the use of our TMA, we surveyed the expression of eukaryotic initiation factor 4E (eIF4E) in OS patients using immunohistochemistry. Aberrant regulation of translation initiation is a feature of many cancers. eIF4E is central to initiation of protein synthesis. Its expression and activity have been implicated in tumor formation and potentially malignant and/or metastatic progression in some carcinomas. We found that eIF4E was uniformly expressed in OS patient samples. No association was found between eIF4E and outcome in OS patients. This novel OS TMA provided a facile mechanism to assess the role of a relevant protein biomarker in OS.Keywords
This publication has 20 references indexed in Scilit:
- Phosphorylated ezrin is located in the nucleus of the osteosarcoma cellLaboratory Investigation, 2010
- Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcomaCancer, 2009
- Muramyl tripeptide (mifamurtide) for the treatment of osteosarcomaExpert Review of Anticancer Therapy, 2009
- Inhibition of Ovarian Cancer Growth by a Tumor-Targeting Peptide That Binds Eukaryotic Translation Initiation Factor 4EClinical Cancer Research, 2009
- Molecular characterization of the response to chemotherapy in conventional osteosarcomas: Predictive value of HSD17B10 and IFITM2International Journal of Cancer, 2009
- Proteomic Analysis of Chemonaïve Pediatric Osteosarcomas and Corresponding Normal Bone Reveals Multiple Altered Molecular TargetsJournal of Proteome Research, 2009
- Expression of Insulin-Like Growth Factor-II mRNA Binding Protein 3 (IMP3) in OsteosarcomaOncology Research, 2008
- Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2008
- Significance of eIF4E expression in skin squamous cell carcinomaCell Biology International, 2007
- Ezrin Expression Predicts Survival in Stage IIB OsteosarcomasClinical Orthopaedics and Related Research, 2007